Expansion Growth Northway Biotech is actively expanding its Lithuania-enabled cell therapy manufacturing footprint with a multi-million dollar investment to establish a 3,500-square-meter center in Vilnius, signaling increased capacity for biologics, ATMPs, and personalized medicine offerings in Northern Europe.

Cell Therapy Focus Recent news highlights a dedicated investment in cell therapy manufacturing and open collaboration with partners on AAV gene therapy, indicating readiness to scale complex biologics manufacturing for gene therapies and ophthalmic indications.

Global CDMO Capabilities With dual-site presence in the US and EU, Northway Biotech offers end-to-end CDMO services from gene to drug, including GMP manufacturing, cell line development, fill and finish, and regulatory CMC support, enabling cross-continent project execution.

Strategic Partnerships Partnerships with gene therapy and ophthalmology-focused companies like Diorasis Therapeutics illustrate a pathway for joint development and scalable manufacturing programs, presenting opportunities for new co-development and toll manufacturing arrangements.

Financial Buzz Revenue is in the tens of millions range, and substantial capital investments in Vilnius signal growing scale and capability, suggesting readiness for larger, multi-phase programs and longer-term engagement opportunities.